170 results
8-K
EX-99.1
TPST
Tempest Therapeutics, Inc.
20 Jun 24
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
8:13am
the third leading cause of cancer death by 2030.3 Every year, more than 900,000 people worldwide are diagnosed with HCC.4 Incidence and mortality … are highest in East Asia and are increasing in parts of Europe and the US.5 In the US, HCC represents the fastest-rising cause of cancer-related death.3
8-K
TPST
Tempest Therapeutics, Inc.
14 Jun 24
Submission of Matters to a Vote of Security Holders
4:41pm
elected and qualified or until their earlier death, resignation or removal. The final voting results were as follows:
Name
Votes For
Votes Withheld
8-K
EX-99.1
TPST
Tempest Therapeutics, Inc.
11 Oct 23
Entry into a Material Definitive Agreement
8:13am
and is projected to become the third leading cause of cancer death by 2030.3 Every year, more than 900,000 people worldwide are diagnosed with HCC.4 … of cancer-related death.3
Nine out of ten cases of HCC are caused by chronic liver disease, which includes chronic hepatitis B and C infection, non
8-K
p4132b7nv 0vx
16 Jun 23
Departure of Directors or Certain Officers
4:22pm
8-K
EX-99.1
qe1osht9q ki0w6
28 Apr 23
Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
8:30am
8-K
g9p4n4qky
21 Jun 22
Departure of Directors or Certain Officers
7:31am
8-K
EX-10.1
1rezhsr 21pdgv
21 Jun 22
Departure of Directors or Certain Officers
7:31am
8-K
EX-10.1
pzb kg9ct
2 May 22
Tempest Announces Private Placement Financing of $15 Million
8:02am